[ASCO]
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
文献作者：Chiun Hsu; Se-Hoon Lee; Samuel Ejadi; Caroline Even; Roger B. Cohen; Christophe Le Tourneau; Janice M. Mehnert; Alain Algazi; Emilie M.J. van Brummelen; Sanatan Saraf; Pradeep Thanigaimani; Jonathan D. Cheng; Aaron R. Hansen
